Open access
Open access
Powered by Google Translator Translator

RCT | Second-line treatment with Axi-cel results in increased overall survival in large B-cell lymphoma

14 Jun, 2023 | 14:25h | UTC

Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma – New England Journal of Medicine (link to abstract – $ for full-text)

News Release: ASCO: Axi-cel significantly improves survival in patients with early relapsed or refractory large B-cell lymphoma – University of Texas MD Anderson Cancer Center

Commentary: Axicabtagene Ciloleucel Improves Overall Survival in Patients With Relapsed or Refractory Large B-Cell Lymphoma – The ASCO Post


Commentary on Twitter


Stay Updated in Your Specialty

Telegram Channels

WhatsApp alerts 10-day free trial

No spam, just news.